Literature DB >> 20946412

Prolonged viral shedding in pandemic influenza A(H1N1): clinical significance and viral load analysis in hospitalized patients.

M Giannella1, M Alonso, D Garcia de Viedma, P Lopez Roa, P Catalán, B Padilla, P Muñoz, E Bouza.   

Abstract

The clinical significance of prolonged viral shedding (PVS) and viral load (VL) dynamics has not been sufficiently assessed in hospitalized patients with pandemic 2009 influenza A(H1N1). We performed a prospective study of adults with confirmed influenza A(H1N1) virus infection admitted to our hospital from 20 September 2009 to 31 December 2009. Consecutive nasopharyngeal swabs were collected every 2 days during the first week after diagnosis, and then every week or until viral detection was negative. Relative VL was measured on the basis of haemagglutinin and RNaseP gene analysis. PVS was defined as positive detection of influenza A(H1N1) virus by real-time RT-PCR at day 7 after diagnosis. We studied 64 patients: 16 (25%) presented PVS. The factors associated with PVS were admission to the intensive-care unit (69% vs. 33%, p 0.02), purulent expectoration (75% vs. 44%, p 0.04), higher dosage of oseltamivir (62.5% vs. 27%, p 0.016), corticosteroid treatment (50% vs. 21%, p 0.05), mechanical ventilation (MV) (50% vs. 12.5%, p 0.004), and longer stay (34 vs. 7 median days, p 0.003). Multivariate analysis revealed the factors independently associated with PVS to be immunosuppression (OR 5.15; 95% CI 1.2-22.2; p 0.03) and the need for MV (OR 11.7; 95% CI 2.5-54.4; p 0.002). VL at diagnosis correlated negatively with age and septic shock. VL dynamics of patients with acute respiratory distress syndrome and/or mortality were very different from those of other patients. PVS was detected in 25% of hospitalized patients with pandemic 2009 influenza A(H1N1) and was strongly associated with immunosuppression and the need for MV. Diagnostic VL and viral clearance varied with the clinical course.
© 2010 The Authors. Clinical Microbiology and Infection © 2010 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Year:  2010        PMID: 20946412     DOI: 10.1111/j.1469-0691.2010.03399.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  39 in total

1.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.

Authors:  Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia
Journal:  Clin Infect Dis       Date:  2019-03-05       Impact factor: 9.079

2.  Con: corticosteroids are not indicated for treatment of acute lung injury from H1N1 viral pneumonia.

Authors:  Michael A Matthay; Kathleen D Liu
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

Review 3.  Re-understanding anti-influenza strategy: attach equal importance to antiviral and anti-inflammatory therapies.

Authors:  Zhengtu Li; Li Li; Shuai Zhao; Jing Li; Hongxia Zhou; Yunhui Zhang; Zifeng Yang; Bing Yuan
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

4.  Viral load at diagnosis and influenza A H1N1 (2009) disease severity in children.

Authors:  Cristian Launes; Juan J Garcia-Garcia; Iolanda Jordan; Laura Selva; Jordi Rello; Carmen Muñoz-Almagro
Journal:  Influenza Other Respir Viruses       Date:  2012-05-24       Impact factor: 4.380

5.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

6.  A comparison of nasopharyngeal and oropharyngeal swabbing for the detection of influenza virus by real-time PCR.

Authors:  S S Hernes; H Quarsten; R Hamre; E Hagen; B Bjorvatn; P S Bakke
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-10-03       Impact factor: 3.267

7.  Animal model of respiratory syncytial virus: CD8+ T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapy.

Authors:  Kevin B Walsh; John R Teijaro; Linda G Brock; Daniel M Fremgen; Peter L Collins; Hugh Rosen; Michael B A Oldstone
Journal:  J Virol       Date:  2014-03-26       Impact factor: 5.103

8.  Prolonged shedding of type 55 human adenovirus in immunocompetent adults with adenoviral respiratory infections.

Authors:  Kyungmin Huh; Inseon Kim; Jaehun Jung; Ji Eun Lee; Byung Woo Jhun; Se Hun Gu; Dong Hyun Song; Eun Young Lee; Ho Jung Jeong; Hongseok Yoo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-01-29       Impact factor: 3.267

Review 9.  Corticosteroids for severe influenza pneumonia: A critical appraisal.

Authors:  Wagner Luis Nedel; David Garcia Nora; Jorge Ibrain Figueira Salluh; Thiago Lisboa; Pedro Póvoa
Journal:  World J Crit Care Med       Date:  2016-02-04

10.  Prolonged shedding of the canine influenza H3N2 virus in nasal swabs of experimentally immunocompromised dogs.

Authors:  Minki Hong; Bokyu Kang; Woonsung Na; Dongjun An; Hyoungjoon Moon; Doo-Jin Kim; Jinsik Oh; Seong-Jun Park; Haryoung Poo; Jeong-Ki Kim; Jongman Kim; Daesub Song
Journal:  Clin Exp Vaccine Res       Date:  2013-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.